The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations

Tuberculosis and Respiratory Diseases

Volumn 59, Issue 3, 2005, Pages 257-265

  Lew, Woo Jin ^a   Park, Young Kil ^a   Kim, Hee Jin ^a   Chang, Chulhun ^a   Bai, Gill Han ^a   Kim, Sung Kyu ^a  

^a Korean Institute of Tuberculosis   (South Korea)

Author keywords

MDR TB; Rifabutin; rpoB mutation

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; CYSTEINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; LEUCINE; PROLINE; RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; SERINE; TYROSINE; VALINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA HYBRIDIZATION; DRUG SENSITIVITY; GENE MUTATION; MULTIDRUG RESISTANCE; NONHUMAN; TUBERCULOSIS;

EID: 26944501240     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2005.59.3.257     Document Type: Article

References (19)

1. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole ST, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
2. Mchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy in pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-30.
3. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-7.
4. Telenti A. Genetics of drug resistance in tuberculosis. In: Iseman MD, Huitt GA, editors. Clinics in chest medicine. Philadelphia: WB Saunders; 1997. p. 55-64.
5. Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987;68:177-82.
6. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuberc Lung Dis 1992;73:59-67.
7. Blumberg HM, Buman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
8. Kim SJ, Bai GH, Hong YP. Drug resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997;1:302-8.
9. Kox LF, van Leeuwen J, Knijper S, Jansen HM, Kolk AH. PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. J Clin Microbiol 1995;33:3225-33.
10. Nolan CM, Williams OL, Cave MD, Eisenach KD, elHajj H, Hooton TM, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995;152:1067-71.
11. Goble M, Iseman D, Madsen LA, Watite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
12. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22 (Suppl 1):S50-4.
13. Dickinson JM, Mitchison DA. In vitro activity of new rifamycin against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987;68:177-82.
14. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicro Chemother 1998;42:621-8.
15. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, et al. Contribution of rpoB mutation to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1853-7.
16. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004;10:662-5.
17. Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999;37:3844-50.
18. Bodmer T, Zurcher G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995;35:345-8.
19. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40:2655-7.